Skip to main content
. 2022 Jun 8;6(11):3440–3450. doi: 10.1182/bloodadvances.2021006434

Figure 6.

Figure 6.

AEs of clinical interest for ibrutinib-treated patients. Any-grade AEs of clinical interest are shown by yearly interval. Prevalence was determined by the proportion of patients with a given AE (existing event or new onset of an event) during each yearly interval. Multiple onsets of the same AE term within a specific yearly interval were counted once, and the same AE term continuing across several yearly intervals was counted in each of the intervals. aCombined terms.